足踝腱鞘巨细胞瘤的多学科管理:两中心最大宗病例回顾
该研究回顾性分析两个肉瘤中心2002年至2019年收治的84例足踝腱鞘巨细胞瘤(TGCT)患者,评估多学科管理下复发率与治疗方式。结果显示弥漫型TGCT复发率最高(61%),关节镜术后复发率47%,系统治疗不良反应常见且停药后可能进展,推荐开放手术作为首选。
要点
- 弥漫型TGCT(Dt-TGCT)复发率61%,全关节受累者复发率83%。
- 关节镜术后复发率47%,开放手术为76例,关节镜为17例。
- 系统治疗用于不可切除或难治病例,86%出现不良反应,停药后36%进展。
核心结论
- 推荐开放手术切除作为足踝TGCT的首选治疗,尤其对弥漫型伴关节外受累者。
- 严重骨软骨破坏可考虑挽救性融合手术,但实际执行较少。
- 系统治疗适用于不可切除或难治性病例,但不良反应常见且停药后可能复发。
研究设计与样本
- 回顾性研究,纳入Oxford肿瘤登记处和Leiden大学医学中心肉瘤登记处2002年1月至2019年8月组织学证实的足踝TGCT患者。
- 共纳入84例患者,男39例,女45例,初次治疗平均年龄38.3岁(范围9至72岁)。
- 中位随访46.5个月(四分位距21.3至82.3个月)。
主要发现
- 局限型TGCT(n=15)主要累及前足,弥漫型TGCT(n=9)倾向于全关节受累。
- 20%(15/75)的病例影像学鉴别诊断未包括TGCT。
- 弥漫型TGCT复发率61%(23/38),全关节受累复发率83%(5/8),关节镜术后复发率47%(8/17)。
- 3例(4%)因弥漫型TGCT导致骨软骨破坏行融合术。
- 14例(16%)弥漫型TGCT患者接受系统治疗,其中79%(11例)为难治性病例;系统治疗后12例(86%)初始缩小或稳定,但5例(36%)随访中进展,均后续手术;12例(86%)报告不良反应。
关键数值与推荐
- 足踝TGCT首选开放手术切除,尤其弥漫型伴关节外受累者。
- 严重骨软骨破坏可考虑挽救性融合手术。
- 系统治疗用于不可切除或难治性病例,但需注意不良反应和停药后复发风险。
临床怎么用
- 对足踝TGCT应提高影像学鉴别诊断意识,避免漏诊。
- 优先选择开放手术而非关节镜,以降低复发风险,尤其弥漫型病例。
- 系统治疗决策需权衡不良反应与停药后进展风险,用于不可切除或难治病例。
局限性
- 回顾性研究设计,存在选择偏倚可能。
- 样本量有限,尤其亚组分析(如全关节受累仅8例)。
- 来自两个专科肉瘤中心,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Tenosynovial giant cell tumour (TGCT) is one of the most common soft-tissue tumours of the foot and ankle and can behave in a locally aggressive manner. Tumour control can be difficult, despite the various methods of treatment available. Since treatment guidelines are lacking, the aim of this study was to review the multidisciplinary management by presenting the largest series of TGCT of the foot and ankle to date from two specialized sarcoma centres. METHODS: The Oxford Tumour Registry and the Leiden University Medical Centre Sarcoma Registry were retrospectively reviewed for patients with histologically proven foot and ankle TGCT diagnosed between January 2002 and August 2019. RESULTS: A total of 84 patients were included. There were 39 men and 45 women with a mean age at primary treatment of 38.3 years (9 to 72). The median follow-up was 46.5 months (interquartile range (IQR) 21.3 to 82.3). Localized-type TGCT (n = 15) predominantly affected forefoot, whereas diffuse-type TGCT (Dt-TGCT) (n = 9) tended to panarticular involvement. TGCT was not included in the radiological differential diagnosis in 20% (n = 15/75). Most patients had open rather than arthroscopic surgery (76 vs 17). The highest recurrence rates were seen with Dt-TGCT (61%; n = 23/38), panarticular involvement (83%; n = 5/8), and after arthroscopy (47%; n = 8/17). Three (4%) fusions were carried out for osteochondral destruction by Dt-TGCT. There were 14 (16%) patients with Dt-TGCT who underwent systemic treatment, mostly in refractory cases (79%; n = 11). TGCT initially decreased or stabilized in 12 patients (86%), but progressed in five (36%) during follow-up; all five underwent subsequent surgery. Side effects were reported in 12 patients (86%). CONCLUSION: We recommend open surgical excision as the primary treatment for TGCT of the foot and ankle, particularly in patients with Dt-TGCT with extra-articular involvement. Severe osteochondral destruction may justify salvage procedures, although these are not often undertaken. Systemic treatment is indicated for unresectable or refractory cases. However, side effects are commonly experienced, and relapses may occur once treatment has ceased. Cite this article: Bone Joint J 2021;103-B(4):788-794.
引用
- Spierenburg G, Lancaster ST, van der Heijden L, et al. Management of tenosynovial giant cell tumour of the foot and ankle. Bone Joint J. 2021. PMID: 33789469. doi:10.1302/0301-620X.103B4.BJJ-2020-1582.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。